The PrEP DC Act of 2025 aims to enhance access to HIV prevention treatments in the District of Columbia by implementing several key provisions. The bill prohibits health benefit plans and insurers from using prescription information as a condition for eligibility or in determining premium rates. Additionally, it prevents insurers from imposing restrictions or delays on the distribution of antiretroviral drugs prescribed for HIV treatment or prevention. Importantly, the legislation also eliminates any cost-sharing requirements, such as deductibles or copayments, for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), thereby making these essential treatments more accessible to individuals at risk of HIV infection.

By establishing these protections, the bill seeks to reduce stigma and discrimination against those seeking HIV prevention treatments, particularly benefiting the LGBTQ community and other high-risk populations. The legislation aligns with ongoing efforts to combat HIV in the District, where approximately 11,670 residents are living with the virus. The bill is expected to take effect 120 days after January 1, 2026, and the Commissioner of the Department of Insurance and Securities Regulation will be responsible for issuing necessary regulations to implement its provisions.